Novotech

CBR International is a consulting firm specializing in drug development for biotechnology and pharmaceutical companies. The company provides technical consulting services in FDA representation, strategic program development, process development, and clinical program development. CBR International's team comprises scientists, engineers, clinicians, and regulatory experts who are committed to advancing scientific knowledge and fostering collaborative teamwork. By offering global product development support, clinical oversight, and strategic regulatory operations, CBR International aims to facilitate efficient and cost-effective product development for its clients.

EastHORN Clinical Services is a full-service contract research organization (CRO) that supports pharmaceutical and biotechnology companies in Europe. The organization specializes in developing treatments across various therapeutic areas, including cardiovascular diseases, dermatology, endocrinology, metabolic diseases, gastroenterology, oncology, and immunology. EastHORN offers a comprehensive range of services, including clinical monitoring, clinical project management, clinical staff provision, and regulatory services. The company is committed to delivering complex studies efficiently and cost-effectively, ensuring that drug development processes meet the needs of its clients.

NCGS, Incorporated is a global full-service clinical research organization (CRO) that offers comprehensive support for clinical development to pharmaceutical, biotechnology, medical device, and diagnostic companies. With over 30 years of experience, NCGS employs a highly skilled team dedicated to delivering studies on time, within budget, and with the highest quality standards. The organization is a WBENC-certified diversity supplier and has successfully supported the approval or expanded labeling of 34 products without receiving any 483s. NCGS emphasizes a collaborative relationship with sponsors, focusing on shared goals and trust, while addressing the complexities of the life sciences sector. The company is committed to protecting research subjects, ensuring data quality, and maintaining scientific integrity. NCGS operates across various therapeutic areas, including oncology-hematology, infectious disease, critical care, and central nervous system disorders, catering to both adult and pediatric populations. The organization aims to enhance clinical efforts by being thorough, timely, and cost-effective, guided by the principle that the products developed could impact the lives of loved ones.

Prospection is a prominent health insights company that specializes in healthcare data analytics, employing predictive analytics and machine learning to extract valuable insights from real-world healthcare data. Established in 2012 in Sydney, Prospection collaborates with government entities, pharmaceutical companies, and the medical community across a wide range of therapy programs, including immuno-oncology, diabetes, respiratory diseases, HIV, and hepatitis, operating in regions such as Australia, Japan, the Asia Pacific, the UK, and the USA. The company offers a software-as-a-service (SaaS) platform that transforms healthcare data into actionable insights, analyzing longitudinal patient data, geo-mapping, and medication utilization. This enables healthcare clients, including pharmaceutical manufacturers and research institutions, to enhance drug performance and improve patient outcomes through innovative data analytics solutions.

ObvioHealth is a global digital health organization focused on enhancing the clinical trial process through innovative technology. The company offers a mobile clinical study application that facilitates site-less trials, enabling participants to engage in remote monitoring from their homes. This application supports continuous data collection, even between scheduled clinic visits, and fosters daily interaction through text messaging and chat features, promoting participant involvement. By connecting with various health devices such as wearables and smart health apps, ObvioHealth ensures comprehensive data gathering. Additionally, the app allows participants to schedule lab visits and manage compensation easily. The overall aim is to streamline the clinical trial process, resulting in improved data quality, increased compliance, faster recruitment, and reduced time to completion, thereby transforming the clinical research landscape.

Clinical Network Services (CNS) Pty Ltd is a Brisbane-based Clinical Research Organisation (CRO) specialising in the planning and implementation of Phase I & II clinical trials in Australia and New Zealand. With over 13 years experience in early stage clinical trial management in more than 145 projects, CNS is one of the most experienced providers within the Australian market and a partner of choice for biotech companies from home and abroad. Small/Medium-sized biotech companies often enter the clinic on a specific budget and therefore need to make sure that money is used efficiently. Australia’s low level of regulatory bureaucracy and the pragmatic review process means that companies can establish initial proof-of-concept quickly, representing a time(cost) saving when compared to the more resource-intensive process when applying for an IND or CTA. In this way, the more involved regulatory processes of USA and Europe can be put to one side until the sponsor has a greater body of evidence and additional funding. CNS has been a leader in the planning, management and implementation of early stage clinical trials in Australia and New Zealand for biotechnology companies from around the world. As an established, niche CRO serving the needs of SME biotech companies, we have a deep understanding of the commercial and scientific challenges that our clients face. CNS provides its biotech clients with the full range of Phase I and Phase II clinical trial services under the “Fast2First” brand and now offers “BioDesk”, a bespoke product development and regulatory planning service which helps our clients efficiently enter the clinic with their lead candidate for the first time and realise commercial goals earlier.